These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 7851087

  • 1. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR.
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC, Chin NX.
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L, Moore T, Niconovich N, Donald B, Broskey J, Jakielaszek C, Rittenhouse S, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [Abstract] [Full Text] [Related]

  • 7. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
    Child J, Andrews J, Boswell F, Brenwald N, Wise R.
    J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
    Gu JW, Fang W, Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1992 Jun; 15(7):613-20. PubMed ID: 1330421
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS, Mazens-Sullivan MF, Bartlett RC.
    Chemotherapy; 1992 Jun; 38(5):308-18. PubMed ID: 1337507
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL, Fuchs PC.
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [Abstract] [Full Text] [Related]

  • 12. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R, Brenwald NP, Andrews JM, Boswell F.
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
    Doebbeling BN, Pfaller MA, Bale MJ, Wenzel RP.
    Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):298-301. PubMed ID: 2112467
    [Abstract] [Full Text] [Related]

  • 15. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Chemotherapy; 1992 May; 38(2):99-106. PubMed ID: 1317282
    [Abstract] [Full Text] [Related]

  • 17. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
    Dembry LM, Roberts JC, Schock KD, Marino SP, Farrel PA, Andriole VT.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
    [Abstract] [Full Text] [Related]

  • 18. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA, Tayeb OS.
    Microbios; 1993 May; 74(300):147-54. PubMed ID: 8396196
    [Abstract] [Full Text] [Related]

  • 19. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP, Cormican MG, Jones RN.
    Ir J Med Sci; 1995 May; 164(4):271-3. PubMed ID: 8522427
    [Abstract] [Full Text] [Related]

  • 20. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
    Johnson DM, Jones RN, Erwin ME.
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):87-91. PubMed ID: 10091031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.